Literature DB >> 14666706

Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.

Jeffrey Cummings1, Alison Ritchie, John Butler, Timothy H Ward, Simon Langdon.   

Abstract

BACKGROUND: RH1 and MeDZQ represent novel aziridinylbenzoquinones that can be activated by DT-diaphorase to form unique DNA lesions. RH1 is due to enter a phase 1 clinical trial in the United Kingdom in the summer of 2003, where pharmacodynamic monitoring of DT-diaphorase will be performed.
MATERIALS AND METHODS: The antitumour efficacy of RH1 and MeDZQ has been studied in 4 human xenografts (3 non-small cell lung cancer and 1 colon cancer), and compared to the level of constitutive DT-Diaphorase activity measured by the DCPIP assay.
RESULTS: The 4 xenografts exhibited a wide range of DT-diaphorase activity (4.8-303 nmol/min/mg). Greater antitumour activity was recorded in the xenografts expressing high levels of DT-diaphorase (e.g. NX002, DT-diaphorase activity, 303 +/- 52 nmol/min/mg, T/C to MeDZQ, 33.3% and to RH1, 43.4%).
CONCLUSION: These data add in vivo support to a role for DT-Diaphorase in the antitumour activity of RH1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666706

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.

Authors:  Moon-Taek Park; Min-Jeong Song; Eun-Taex Oh; Hyemi Lee; Bo-Hwa Choi; Seong-Yun Jeong; Eun-Kyung Choi; Heon Joo Park
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

2.  Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.

Authors:  D Hussein; S V Holt; K E Brookes; T Klymenko; J K Adamski; A Hogg; E J Estlin; T Ward; C Dive; G W J Makin
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

3.  Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).

Authors:  Chao Yan; Jadwiga K Kepa; David Siegel; Ian J Stratford; David Ross
Journal:  Mol Pharmacol       Date:  2008-09-15       Impact factor: 4.436

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.